An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A 43-year-old man tried a short course of a peptide called tesamorelin and tracked a blood marker called IGF‑1 (a hormone-related protein). He started on a low dose for a month and saw a modest rise in IGF‑1. Then he doubled the tesamorelin dose for another month and saw a much bigger jump than he expected. After those tests he stopped the treatment to try something else. Tesamorelin is a lab-made version of a natural hormone that tells the body to make growth-hormone–releasing hormone (GHRH) activity. In plain terms, it nudges your pituitary gland to release growth hormone, and that in turn raises levels of IGF‑1 (insulin-like growth factor 1), which is a messenger that carries many of growth hormone’s effects. It’s not the same thing as taking growth hormone directly; it works by stimulating your own hormone system. It’s given as a small injection under the skin (subcutaneous). The “study” here is essentially a single-person observation over about eight weeks: four weeks at 1 mg tesamorelin plus 250 mcg of something labeled IPA five days a week, then four weeks at 2 mg with the same 250 mcg IPA schedule. His IGF‑1 went from 207 ng/dL at baseline to 250 ng/dL after the lower dose, then jumped to 373 ng/dL after the higher dose. That increase wasn’t linear or proportional, meaning doubling the drug didn’t just double the effect — the response was larger than expected. This is anecdotal data from one person, not a controlled trial, so it’s interesting but limited evidence. Why this might matter: IGF‑1 and growth‑hormone signaling affect body composition, energy, and aging in complex ways. Doctors sometimes use tesamorelin for people with specific problems (for example, it was approved in some places to reduce visceral fat in people with HIV). For someone exploring hormone optimization or treating a medical condition linked to low growth-hormone activity, the strong rise in IGF‑1 at a higher dose is a reminder that small dose changes can have big effects on lab numbers. Clinicians and patients who monitor hormone levels would care because it shows a real biochemical response to dose adjustments. There are important caveats and risks. This report is just one person’s labs, not randomized or blinded research. Higher IGF‑1 isn’t automatically good — too much can raise risks like insulin resistance, joint pain, fluid retention, and possibly other long-term risks. Tesamorelin is a prescription medication in some settings and not approved for casual anti‑aging or bodybuilding use. People with certain cancers, pregnant people, or those with specific health issues should avoid hormone-stimulating drugs unless supervised by a doctor. Lab monitoring and medical oversight are essential; stopping or changing doses should be done under guidance. Bottom line: One man’s brief experiment shows tesamorelin can produce a disproportionately large rise in IGF‑1 when the dose was doubled, but this is an isolated observation and not evidence that the change is safe or beneficial for others.
Source: r/Peptides